We are live on ! Find out more
ZVRA icon

Zevra Therapeutics

40 hedge funds and large institutions have $24.8M invested in Zevra Therapeutics in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 9 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 9

31% less funds holding

Funds holding: 5840 (-18)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

77% less capital invested

Capital invested by funds: $106M → $24.8M (-$81.4M)

78% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 23

Holders
40
Holders Change
-18
Holders Change %
-31.03%
% of All Funds
1.07%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
5
Increased
18
Reduced
9
Closed
23
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
ProShare Advisors
26
ProShare Advisors
Maryland
$43K +$2.63K +16 +2%
CS
27
Credit Suisse
Switzerland
$41K -$248K -1,508 -70%
Creative Planning
28
Creative Planning
Kansas
$35K
Deutsche Bank
29
Deutsche Bank
Germany
$21K -$64.8K -394 -53%
Morgan Stanley
30
Morgan Stanley
New York
$16K -$89.5K -544 -69%
WCM
31
Wealthcare Capital Management
Virginia
$8K +$10.2K +62 +98%
BIM
32
BlackRock Investment Management
Delaware
$8K +$10.9K +66 +106%
Royal Bank of Canada
33
Royal Bank of Canada
Ontario, Canada
$8K +$20.6K +125 +2,083%
Citigroup
34
Citigroup
New York
$7K -$823 -5 -4%
TIM
35
Tortoise Investment Management
New York
$7K
Bank of America
36
Bank of America
North Carolina
$6K +$14.8K +90 New
CG
37
Cutler Group
California
$3K +$8.23K +50 New
BA
38
BlackRock Advisors
Delaware
$2K
Manulife (Manufacturers Life Insurance)
39
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2K
Barclays
40
Barclays
United Kingdom
$1K +$987 +6 +120%
Schroder Investment Management Group
41
Schroder Investment Management Group
United Kingdom
-$5.14M -21,419 Closed
BC
42
Broadfin Capital
New York
-$4.35M -18,731 Closed
SFM
43
Sphera Funds Management
Israel
-$2.67M -11,497 Closed
ECM
44
Endurant Capital Management
California
-$2.46M -10,599 Closed
Wellington Management Group
45
Wellington Management Group
Massachusetts
-$912K -3,931 Closed
KCM
46
Kennedy Capital Management
Missouri
-$799K -3,445 Closed
CI
47
Cowen Inc
New York
-$789K -3,402 Closed
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
-$715K -3,082 Closed
MCM
49
Moore Capital Management
New York
-$595K -2,563 Closed
BG
50
BlackRock Group
United Kingdom
-$593K -2,556 Closed

ZVRA Hedge Fund Activity: Q2 2016 in Review

40 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q2 2016, worth a combined $24.8M — down 77% from $106M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of ZVRA and 5 opened new positions — a net loss of 18 holders — while 9 trimmed existing stakes and 18 added.

The largest buyer was Alyeska Investment Group, adding an estimated $4.09M. The largest seller was Schroder Investment Management Group, exiting entirely with an estimated $5.14M sold.

  • 40 institutional investors held Zevra Therapeutics (ZVRA) as of Q2 2016, down from 58 in Q1 2016.
  • Funds reported $24.8M of Zevra Therapeutics stock for Q2 2016, down 77% quarter-over-quarter.
  • 5 funds opened new Zevra Therapeutics positions in Q2 2016 and 23 closed out, a net change of -18 holders.
  • The largest Zevra Therapeutics buyer in Q2 2016 was Alyeska Investment Group, an estimated $4.09M added.
  • The largest Zevra Therapeutics seller in Q2 2016 was Schroder Investment Management Group, an estimated $5.14M sold.

Based on aggregated 13F filings for Q2 2016.